MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.
코호트
1/5 보강
[PURPOSE] Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging.
APA
Huang K, Ma H, et al. (2025). MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.. Journal of cancer research and clinical oncology, 151(9), 251. https://doi.org/10.1007/s00432-025-06306-7
MLA
Huang K, et al.. "MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.." Journal of cancer research and clinical oncology, vol. 151, no. 9, 2025, pp. 251.
PMID
40931250 ↗
Abstract 한글 요약
[PURPOSE] Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
[METHODS] This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients). Radiomics features were extracted using a Pyradiomics-based system. Biopsy specimens were used for immunohistochemical staining of epidermal growth factor receptor. Risk factors for predicting treatment response were screened out to construct models by logistic regression analysis. The performance of models was evaluated with receiver operating characteristic and decision curve analyses.
[RESULTS] A total of 9370 radiomics features were extracted from five sequences. Subsequently, seven radiomics features were identified for modeling. Intratumoral vessel and expression level of epidermal growth factor receptor were independent risk factors for predicting treatment response to lenvatinib and were used to build a clinical model. No difference was found in predicting performance between clinical model and radiomics model. The combined model, integrating intratumoral vessel, epidermal growth factor receptor and radiomics features, had better predicting performance with areas under the receiver operating characteristic curve of 0.908, 0.877, and 0.870 for the training, internal test and external test sets, respectively.
[CONCLUSION] This study underscored the significant potential of radiomics features combined with clinicoradiological indicators in the prediction of treatment response to lenvatinib in patients with hepatocellular carcinoma.
[METHODS] This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients). Radiomics features were extracted using a Pyradiomics-based system. Biopsy specimens were used for immunohistochemical staining of epidermal growth factor receptor. Risk factors for predicting treatment response were screened out to construct models by logistic regression analysis. The performance of models was evaluated with receiver operating characteristic and decision curve analyses.
[RESULTS] A total of 9370 radiomics features were extracted from five sequences. Subsequently, seven radiomics features were identified for modeling. Intratumoral vessel and expression level of epidermal growth factor receptor were independent risk factors for predicting treatment response to lenvatinib and were used to build a clinical model. No difference was found in predicting performance between clinical model and radiomics model. The combined model, integrating intratumoral vessel, epidermal growth factor receptor and radiomics features, had better predicting performance with areas under the receiver operating characteristic curve of 0.908, 0.877, and 0.870 for the training, internal test and external test sets, respectively.
[CONCLUSION] This study underscored the significant potential of radiomics features combined with clinicoradiological indicators in the prediction of treatment response to lenvatinib in patients with hepatocellular carcinoma.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Liver Neoplasms
- Carcinoma
- Hepatocellular
- Phenylurea Compounds
- Female
- Male
- Quinolines
- Middle Aged
- Retrospective Studies
- Aged
- Magnetic Resonance Imaging
- Adult
- Nomograms
- Antineoplastic Agents
- Molecular Targeted Therapy
- Treatment Outcome
- Prognosis
- Radiomics
- Epidermal growth factor receptor
- Hepatocellular carcinoma
- Lenvatinib
같은 제1저자의 인용 많은 논문 (5)
- Novel Toxicokinetics and Metabolic Insights Into Arsenic in Biological Systems From Realgar-Indigo naturalis Formula.
- HBx Promotes Liver Cancer Cells to Escape NK-92 Cell Attack by Mediating ADAM10 to Enzyme Cut MICA/B Shedding From Cancer Cell Membrane.
- Extrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma: a multi-omics analysis and prognostic model development.
- PTMA safeguards mitochondrial integrity to sustain metabolic function and antitumor activity of CD8 T cells.
- Pulmonary microbiota, local inflammation, and tumor progression impact immune checkpoint gene profiles in the lung microenvironment.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.